In this context, an analysis of SAFEHEART (Spanish Familial Hypercholesterolemia Cohort Study), including 2927 family members from 755 index FH cases, investigated whether testing for Lp(a) was effective in detecting and risk-stratifying individuals participating in a FH cascade screening program [78]. The gene discussed is LPA; the disease is familial hyperaldosteronism.